Clinical trials: Relapsed Leukemia
Acute Myeloid Leukemia, Relapsed AML
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML).
- Conditions
- Acute Myeloid Leukemia, Relapsed AML, Refractory AML
- Trial name
- NCT03516760
- Testing
- GEM333
- Where
- 7 sites in Germany
- Volunteers
- 36 people
- Sponsor
- AvenCell Europe GmbH
Follicular Lymphoma, Chronic Lymphocytic Leukemia
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
This study will evaluate the safety and tolerability of GS-9901 monotherapy in adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL).
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT02258555
- Testing
- GS-9901
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gilead Sciences
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT04988555
- Testing
- Enzomenib, azoles, Venetoclax
- Where
- 104 sites in United States, Belgium and 10 more
- Volunteers
- 606 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Lymphocytic Leukaemia, Patients Resistant to a Purine Analogous
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
Since there is no standard rescue therapy for refractory CLL or relapsed to the purine analogous, our target is to carry out a rescue therapy combining several chemotherapy agents (CHOP) adding the synergistic effect of Rituximab…
- Conditions
- Chronic Lymphocytic Leukaemia, Patients Resistant to a Purine Analogous, Patients Relapsed With Purines Therapy
- Trial name
- R-CHOP (NCT00504491)
- Testing
- Rituximab-CHOP-Alemtuzumab
- Where
- 32 sites in Spain
- Sponsor
- CABYC
Acute Myeloid Leukemia
A Study of TAS1440 With ATRA in Subjects With r/r AML
This is a multicenter, 2-part, Phase 1 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of TAS1440 administered as a single agent and in combination with all-trans retinoic acid…
- Trial name
- NCT04282668
- Testing
- TAS1440, TAS1440 + ATRA
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Acute Myeloid Leukemia
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML).
- Trial name
- NCT04155580
- Testing
- ASTX660, ASTX727
- Where
- 15 sites in United States
- Volunteers
- 68 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or…
- Trial name
- NCT04477291
- Testing
- CG-806
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab)…
- Trial name
- CaDAnCe-303 (NCT06970743)
- Testing
- BGB-16673, Bendamustine, Rituximab
- Where
- 56 sites in China, Taiwan
- Volunteers
- 153 people
- Sponsor
- BeOne Medicines
T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
This is a single dose escalation study to evaluate the safety and clinical activity of ThisCART7(Allogeneic CAR-T targeting CD7) in patients with refractory or relapsed CD7 positive T cell malignancies.
- Conditions
- T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Lymphoma
- Trial name
- NCT05127135
- Testing
- ThisCART7 cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Fundamenta Therapeutics, Ltd.
Central Nervous System Lymphoma
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
This study is a open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of Human CD19-CD22 Targeted T Cells by intravenous and intrathecal administration, and to…
- Trial name
- NCT05651178
- Testing
- Human CD19-CD22 Targeted T Cells Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
This is a Phase I/II, single-arm, multicenter, open-label study which is divided into two portions: Phase I is dose escalation portion, in which subjects with relapsed or refractory B-cell lymphoma will be enrolled except…
- Conditions
- Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
- Trial name
- NCT05720052
- Testing
- MS-553
- Where
- China
- Volunteers
- 8 people
- Sponsor
- MingSight Pharmaceuticals, Inc
Acute Myeloid Leukemia
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
1. To evaluate the safety and tolerability of xy0206 as single drug in the treatment of relapsed / refractory AML; 2. Evaluate the dose limited toxicity (DLT) and maximum tolerable dose (MTD) of xy0206 as single drug in the…
- Trial name
- NCT04471064
- Testing
- XY0206
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Acute Myeloid Leukemia, Myeloproliferative Neoplasm
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
This is a Phase 1, 2-part, open-label, multicenter, first-in-human (FIH) study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of TAS1553 administered orally to participants…
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT04637009
- Testing
- TAS1553
- Where
- 10 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Leukemia, B-cell
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
This is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of targeted CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19/CD22 positive Relapsed or…
- Trial name
- NCT03614858
- Testing
- CART-19/22
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 in paediatric or young adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia
- Trial name
- AMELIA (NCT03289455)
- Testing
- AUTO3 (CD19/22 CAR T cells
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Autolus Limited
Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic
Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma
In Japan, patients with relapsed or refractory T-ALL/T-LBL represent an extremely small patient population. While the small number of patients presents a practical limitation to the size of a clinical trial, patients whose…
- Trial name
- NCT00406757
- Testing
- Nelarabine injection 400mg/m2, Nelarabine injection 650mg/m2, Nelarabine injection 1000mg/m2
- Where
- 3 sites in Japan
- Volunteers
- 13 people
- Sponsor
- GlaxoSmithKline
Chronic Lymphocytic Leukemia, CLL
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
TP-0903 is an inhibitor of AXL kinase. TP-0903 has shown potent inhibition of AXL kinase and other TAM family members in a biochemical kinase assay.
- Conditions
- Chronic Lymphocytic Leukemia, CLL, SLL, Small Lymphocytic Lymphoma
- Trial name
- NCT03572634
- Testing
- TP-0903, TP-0903 and ibrutinib combination therapy
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), B-Cell Non-Hodgkin Lymphomas(NHL)
- Trial name
- NCT03588598
- Testing
- SHC014748M
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Primary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic…
- Trial name
- ISAKIDS (NCT03860844)
- Testing
- Isatuximab, Dexamethasone or equivalent, Fludarabine
- Where
- 41 sites in United States, Argentina and 14 more
- Volunteers
- 67 people
- Sponsor
- Sanofi
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the…
- Trial name
- AMpLify (NCT06128044)
- Testing
- CB-012
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- Caribou Biosciences, Inc.